EnligHTN German Observational Study of Renal Denervation for Uncontrolled Hypertension

NCT01996033 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2019-02-04

Study results available
· View outcomes & findings →

Summary

The purpose of this observational study is to further evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with uncontrolled hypertension in clinical routine practice.

Conditions

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Christoph K Naber, MD · Elisabeth-Krankenhaus Essen, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01996033 on ClinicalTrials.gov